[Skip to Content]
[Skip to Content Landing]
Views 270
Citations 0
Comment & Response
October 25, 2016

Colorectal Cancer Screening

Author Affiliations
  • 1National Cancer Institute, Bethesda, Maryland
JAMA. 2016;316(16):1715. doi:10.1001/jama.2016.13849

To the Editor In both the USPSTF recommendation statement for CRC screening1 and the accompanying evidence review,2 little mention was made of an important aspect of CRC screening, namely that it has been shown to reduce CRC incidence as well as mortality. A prior meta-analysis of one modality, flexible sigmoidoscopy, showed a range of incidence RRs from 4 randomized clinical trials of 0.73 to 0.82, with all but 1 RR being statistically significant, and an overall combined incidence RR of 0.78 (95% CI, 0.74-0.83).3 These are the same trials whose mortality results were discussed in the evidence review, with a combined mortality RR of 0.73 (95% CI, 0.66-0.82).

First Page Preview View Large
First page PDF preview
First page PDF preview